Pluristem Appoints Diabetic Neuropathy And Vascular Disease Expert, Dr. Aristidis Veves, To Its Scientific Advisory Board
Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it appointed Dr. Aristidis Veves to the company’s Scientific Advisory Board.
Dr. Veves brings more than 30 years of experience in the field of diabetic neuropathy and vascular disease. An expert in diabetic foot problems and vascular reactivity, Dr. Veves is the research director of the Joslin-Beth Israel Deaconess Foot Center and of the Microcirculation Lab, as well as an associate professor at Harvard Medical School. Dr. Veves’ research focuses on techniques that will identify patients at risk of developing diabetic foot problems at the early stages and therapeutic strategies that will prevent or slow the progression of this condition.
“Dr. Veves is a highly regarded thought leader in diabetic neuropathy and vascular disease, common in patients with Critical Limb Ischemia (CLI),” said Dr. Edwin Horwitz, Chairman of Pluristem’s Scientific Advisory Board. “His appointment to our advisory board will bring invaluable expertise and perspective in diabetic neurological conditions and wound care that will be necessary as Pluristem progresses through clinical studies with its placenta-derived cell therapies.”
Dr. Veves added, “Clinical results suggest that Pluristem’s product for peripheral artery disease, PLX-PAD, is potentially a safe, well tolerated and effective treatment for patients with diabetic foot and wound healing problems. I look forward to contributing to PLX-PAD’s clinical advancement as well as helping apply Pluristem’s technology to other neurological and wound care indications.”Zami Aberman, Chairman and CEO of Pluristem, added: “We at Pluristem are extremely pleased that a researcher of Dr. Veves’ caliber is joining our Scientific Advisory Board and we believe his contributions will be valuable as we enter the neurologic and wound care markets with our PLX cells.” About Pluristem Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s proprietary and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. In April 2010, Pluristem reported interim top-line results from Phase I clinical trials of PLX-PAD that demonstrated the cell therapy is potentially safe, well tolerated and effective in patients with critical limb ischemia (CLI).
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV